scholarly journals Urinary incontinence associated with pharmacological treatment of Chronic Obstructive Lung Disease: An integrative review

2021 ◽  
Vol 10 (9) ◽  
pp. e3810917558
Author(s):  
Phydel Palmeira Carvalho ◽  
Roberto Bandeira Tosta Maciel ◽  
Gabriel Couto Rocha ◽  
Murilo de Jesus Porto ◽  
Juliana Santana Montalvão Galliza ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Urinary Incontinence ◽  
Adverse Effects ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Pharmacological Treatment ◽  
Randomized Clinical Trials ◽  
Integrative Review ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a lung disease, often associated with smoking. COPD patients have persistent, including urinary incontinence. Therefore, a research has the general objective of knowing the physiological mechanism of urinary incontinence associated with the pharmacological treatment of COPD. As a methodological process, this study is an integrative review that included randomized clinical trials, quasi-experimental intervention studies, cohort and case-control. The selection of studies was carried out in the databases PubMed, SciELO, Science Direct and BVS (Virtual Health Library), published between 2010 and July 2020, in Portuguese and English. Pharmacological classes SABA, LABA, SAMA, LAMA, ICS and iPDE4 were considered to investigate adverse effects and check for the presence of urinary symptoms caused by these drugs. In the results and discussion, 113 articles were identified with the investigated descriptors. After the article selection process, 14 studies resulted: PubMED (13); and Science Direct (1). The pharmacological class related to urinary incontinence identified in this study was that of anticholinergics / antimuscarinics. From this perspective, it can be considered that Urinary Incontinence has a low relationship with the adverse effects of drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD). However, as urinary incontinence is not considered a life-threatening problem, it is possible that it has not been included among the adverse events to be explored.

scholarly journals Pharmacological treatment and current controversies in COPD

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1533 ◽  
Author(s):  
Mario Cazzola ◽  
Paola Rogliani ◽  
Daiana Stolz ◽  
Maria Gabriella Matera
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Pharmacological Treatment ◽  
Obstructive Lung Disease ◽  
Chronic Obstructive Lung Disease ◽  
New Drugs ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Global Initiative

Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of decisively influencing the course of the disease. However, in recent years, information has been produced that, if used correctly, can allow us to improve the use of the available therapies.

scholarly journals Chronic Obstructive Pulmonary Disease Combined With Interstitial Lung Disease

2021 ◽  
Author(s):  
Joon Young Choi ◽  
Jin Woo Song ◽  
Chin Kook Rhee
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Interstitial Lung Disease ◽  
Pulmonary Fibrosis ◽  
Lung Disease ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Quit Smoking ◽  
Lung Abnormalities ◽  
Pharmacologic Agents

Although chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) have distinct clinical features, both diseases may coexist in a patient because they share similar risk factors such as smoking, male sex, and old age. Patients with both emphysema in upper lung fields and diffuse ILD are diagnosed with combined pulmonary fibrosis and emphysema (CPFE), which causes substantial clinical deterioration. Patients with CPFE have higher mortality compared with patients who have COPD alone, but results have been inconclusive compared with patients who have idiopathic pulmonary fibrosis (IPF). Poor prognostic factors for CPFE include exacerbation, lung cancer, and pulmonary hypertension. The presence of interstitial lung abnormalities, which may be an early or mild form of ILD, is notable among patients with COPD, and is associated with poor prognosis. Various theories have been proposed regarding the pathophysiology of CPFE. Biomarker analyses have implied that this pathophysiology may be more closely associated with IPF development, rather than COPD or emphysema. Patients with CPFE should be advised to quit smoking and undergo routine lung function tests, and pulmonary rehabilitation may be helpful. Various pharmacologic agents may be beneficial in patients with CPFE, but further studies are needed.

Sign in / Sign up

Export Citation Format

Share Document